NCT03061188 - Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 23, 2017

Primary Completion Date

March 11, 2018

Study Completion Date

August 4, 2020

Conditions

Advanced Solid NeoplasmAggressive Non-Hodgkin LymphomaRecurrent Solid NeoplasmRefractory Mantle Cell LymphomaT-Cell Non-Hodgkin LymphomaUnresectable Solid Neoplasm

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

OTHER

Pharmacological Study

Correlative studies

DRUG

Veliparib

Given PO

Trial Locations (1)

60611

Northwestern University, Chicago